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Abstract
RNA interference can be mediated by fully complementary siRNA or partially complementary miRNA. siRNAs are widely used
to suppress viral replication and the fully complementary siRNA bound Ago-2 in the RISC is known to degrade the target
RNA. Although other argonaute proteins lacking slicer activity can also bind oligonucleotides with both si and miRNA
structures, whether they can also contribute to antiviral effects is not entirely clear. We tested si and miRNA structured
oligos for target repression in dual luciferase assays as well as for inhibition of Dengue and West Nile virus replication in ES
cells expressing individual Ago proteins. In luciferase assays, both fully complementary and partially complementary oligos
effectively repressed their targets in all individual Ago expressing cell lines, although the efficacy with fully complementary
oligos was higher in Ago-2+ cells. However, partially complementary oligos had no effect on virus replication in any cell line,
while fully complementary siRNAs were highly effective in Ago-2 expressing, but not in cells expressing other Ago proteins.
This occurred irrespective of whether the target sequences were located in the coding region or 39UTR of the virus. We
conclude that Ago-2 slicer activity is essential for anti-viral efficacy of siRNAs and miRNA-mediated translational repression/
transcript destabilization is too weak to suppress the abundantly expressed flaviviral proteins.
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Introduction
RNA interference (RNAi) is a phenomenon where small double
stranded RNAs mediate sequence-specific regulation of gene
expression. Essentially, RNAi can be induced either by endoge-
nously encoded small RNAs called microRNAs (miRNAs),
endogenously generated small interfering siRNAs (siRNA) or
exogenously introduced siRNAs [1,2,3,4]. In either case, the 21–
23 nucleotide dsRNAs associate in the cytoplasm with the RNA-
induced silencing complex (RISC), whereupon one of the two
RNA strands (passenger strand) is discarded and the other guide
strand guides the RISC to mediate sequence-specific degradation
of the corresponding mRNA (in the case of siRNAs) and/or
translational repression/transcript destabilization by binding to
the 39 untranslated region (UTR) (in the case of miRNAs) [5,6].
While siRNAs are designed to be fully complementary to the
coding region of the mRNA target to be silenced, miRNAs are
imperfectly complementary, generally having sequence matches in
the 59 2-8nt seed sequence to the 39UTR of the target mRNA.
Also, while siRNAs primarily degrade the target mRNA, miRNAs
lead to translational repression/mRNA destabilization (reviewed
in [7]). Thus, although both mi and siRNAs use the same RNAi
machinery, the exact mechanism of gene silencing is different.
Argounate (Ago) proteins are key constituents of the RISC and
mammalian cells contain 4 Ago proteins, Ago1-4. Recent studies
suggest that both si and miRNAs are indiscriminately loaded into
all 4 Ago proteins in mammalian cells [8,9]. However, since only
mammalian Ago-2 has slicer activity, the role of other Ago
proteins in the siRNA pathway is unclear.
One of the important applications of siRNAs is to suppress viral
infection and proof of concept studies in cell lines, and various
animal models including mice, monkeys and chimpanzees suggest
that virtually any viral infection can be effectively silenced
(reviewed in [10]). In fact, the recently concluded Phase II human
clinical trial for RSV infection also underscores the antiviral
potential of siRNAs [11]. Several cellular miRNAs have also
been reported to affect the replication of different (primate foamy
virus, influenza virus, hepatitis B, HIV and HSV) viruses
[12,13,14,15,16,17,18]. Generally the miRNAs have perfect or
imperfect homology in the seed region to their target sites in the
viral coding region or 39UTR. Despite this, the miRNAs repress
the virus by either transcript degradation (even with only seed
matches) or translational repression. Thus, the exact mechanism of
miRNA mediated viral repression and which Ago proteins are
involved remain poorly understood. As described earlier, siRNAs
are designed to be perfectly homologous to the target sequence
and the targets are therefore amenable to be degraded by Ago-2.
However, whether siRNAs bound to other Ago proteins or
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only partially complementary at the ‘‘seed sequence’’ in the target)
can also be used to suppress viral infection is not known [19,20].
Although miRNAs were thought to bind to their target in the
39UTR, recent data from several laboratories suggest that seed
matches in the coding region can also serve as effective targets for
miRNAs [21,22,23,24]. In fact as mentioned earlier, several
cellular miRNAs that are known to repress viral replication also
bind to viral coding regions. If miRNA-mediated translational
repression/transcript destabilization can be used in conjunction
with siRNA mediated transcript degradation, it could enormously
enhance RNAi antiviral efficacy. Thus, in this study, ES cells
expressing individual Ago proteins were tested for suppression of
viral replication by fully complementary siRNAs or partially
complementary oligos resembling miRNAs.
Results
All the 4 mammalian Ago proteins can mediate target
repression by oligonucleotides with both si and miRNA
structures in reporter assays
We have previously identified siRNAs that potently suppress
dengue and West Nile virus infection in vitro and in vivo
[25,26,27]. To test whether the different Ago proteins can bind si
and miRNA structured oligonucleotides and mediate target
repression, we used a dengue virus siRNA as base. We constructed
a dual luciferase reporter with 1 copy of fully complementary
target sites for dengue siRNA (siFvE
D) in the renilla luciferase
39UTR. This plasmid was transfected along with fully comple-
mentary or partially complementary dengue virus siRNA
(sequence differing at nts 9-11, Table 1) into ES cells expressing
only Ago-1, Ago-2, Ago-3 or Ago-4 [9] and analyzed for target
repression after 24h. Partially complementary dengue miRNA
mimicking siRNA could repress the target (40–60%) in cells
expressing individual or all the Ago proteins (Fig. 1). Although
fully complementary siRNA also repressed the target to a similar
extent in Ago-1, Ago-3 and Ago-4 expressing cells, the target
repression was more profound in Ago-2 and in all 4 Ago
expressing cells (.90%). Thus, oligonucleotides with both si and
miRNA structure can bind to all the Ago proteins and repress
targets, although the efficacy is highest for siRNAs in Ago-2
expressing cells.
Only Ago-2 bound fully complementary siRNAs suppress
viral replication
Because in the reporter assay, both si and miRNA structured
oligos repressed targets in all individual Ago expressing cells, we
tested if these oligos could also suppress viral infection. First we
determined that all individual Ago expressing cells were
susceptible to virus infection, although for unknown reason, the
parental ES cells expressing all Ago proteins showed the lowest
levels of infection (Fig 2A). To test antiviral efficacy of RNAi, all or
individual Ago expressing cells were transfected with dengue si or
mi RNA mimicking oligos, infected with dengue virus 24h later
and assessed for infection 72h after infection. To detect infection,
cells were stained with a dengue virus envelope-specific monoclo-
nal antibody and analyzed by FACS. As shown in Fig 2A, the fully
complementary siRNA effectively suppressed the virus replication
in Ago-2 and all Ago protein expressing parental cell line.
However, the siRNA did not significantly affect virus replication in
Ago-1, Ago-3 or Ago-4 expressing cells and the miRNA structured
oligos failed to significantly suppress virus replication in any of the
individual Ago expressing cell line.
One reason why the miRNA resembling siRNA failed to
suppress virus replication in the above experiment is that both the
si and miRNAs were designed to target the coding region in the
virus (encoding the viral envelop gene), whereas endogenous
miRNAs generally target the 39UTR sequences. To test if this is
indeed the case, we also tested si/miRNA resembling oligos that
target the viral 39 UTR. Initially we tested several potential
siRNAs targeting West Nile virus 39 UTR and identified one that
potently suppressed viral replication in HeLa cells (not shown). We
used this siRNA and its counterpart miRNA structure (Table 1) for
virus inhibition in individual Ago expressing cells by FACS
analysis as well as testing the culture supernatants for released
virus particles by qPCR. Even in this case, the completely
complementary siRNA effectively suppressed virus replication in
all 4 Ago expressing parental cell line and Ago-2 only expressing
cells, but failed to significantly inhibit the virus in Ago 1, Ago 3
and Ago 4 expressing cells (Fig 2B and 2C). Moreover, the miRNA
resembling siRNA failed to suppress virus replication in all cell
lines. These results are not due to variability in the transfection
efficiency in different cell lines, because all the individual Ago
expressing cells were equally amenable for transfection with FITC
labeled siRNA (Fig. 2D). Taken together, our results suggest that
siRNAs designed to mimic miRNA structure fail to inhibit
flavivirus replication whether the target is in the coding region
or 39 UTR.
We also tested 2 additional siRNAs that we had earlier
identified as potent suppressors of West Nile virus (WNV)
[26,28]. Even in this setting, both the tested siRNAs effectively
inhibited WNV infection in Ago-2 expressing cells and the
parental cell line, while they were ineffective in other Ago
expressing cells (Fig. 2E). Thus Ago-2 mediated target cleavage
appears to be essential for antiviral efficacy of siRNAs. These
results also suggest that siRNAs bound to Agos 1, 3 and 4 only
serve to dilute the siRNA effect.
Although P-bodies are lost following flaviviral infection,
RNAi function is not affected
Many of the proteins involved in the RNAi pathway accumulate
in discrete cytoplasmic bodies called the processing or P bodies
[29]. Moreover GW182, a key component of the P- body,
associates with all Ago proteins as well as with mRNA and is
essential for miRNA-mediated target repression [30]. A recent
report suggests that flavivirus infection leads to loss of stress
granules as well as P bodies [31]. We therefore tested if P bodies
are indeed lost following flaviviral infection and if this could be
why the miRNA mimicking siRNAs are ineffective in silencing
viral replication. Compared to control HeLa cells, in HeLa cells
infected with dengue or WNV, P bodies were dramatically
diminished as revealed by staining with DCP-1 antibody (Fig 3A).
Table 1. Sequence of siRNA and miRNA mimicking
oligonucleotides.
siRNA/miRNA sense strand sequence (59R39)
siFvE
D ggatgtggattatttggaa
miFvE
D ggatgtggtaaatttggaa
siWN-3UTR tgtagtgttcatagcaatt
miWN-3UTR tgtagtgtagttagcaatt
SiRNAs were designed to completely match the target sequence, while miRNA
mimicking siRNAs were designed to contain central 3 mismatches (nts 9-11-nts
depicted in bold letters).
doi:10.1371/journal.pone.0027551.t001
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WNV replicon (not shown), confirming the previous report as well
as showing that introduction of the replicon is sufficient to induce
the loss of P bodies. To test if the loss of microscopically visible P
bodies is due the loss of GW182, we also performed qRT-PCR
and Western blot for GW182. GW182 mRNA as well as protein
levels were not decreased in replicon containing cells as compared
to control HeLa cells (Fig 3B). We also tested if RNAi machinery is
ineffective because of loss of P bodies. si/miRNA mimicking
oligonucleotides were transfected into dengue replicon expressing
cells along with the luciferase construct containing the target
sequence in the 39UTR. As shown in Fig 3C, both si and miRNA
structured oligos were effective in repressing luciferase although as
expected, siRNA was more effective than miRNA structured oligo.
Collectively, these results suggest that although microscopic P
bodies were diminished in infected cells, the GW182 protein itself
was not and it did not affect the RNAi response. This finding is
also consistent with a recent report in drosophila S2 cells that
suggests that P-body formation is a consequence rather than the
cause of RNAi-mediated silencing [32].
Discussion
Our results suggest that although effective in reporter assays,
completely complementary siRNAs loaded to Agos1, 3 and 4 and
siRNAs mimicking miRNAs with only seed matches to the viral
targets in the coding region or 39UTR loaded to any of the Agos
fail to suppress an acute flaviviral infection.
Because only Ago-2 has slicer activity and also because
extensive pairing with the target is required for slicing, siRNAs
bound to Ago-2 can degrade the target mRNA whereas siRNAs
bound to Agos 1, 3 and 4 as well as miRNAs bound to any Ago
protein can only mediate target repression by translational
repression/transcript destabilization [5]. Intrinsically, miRNAs
are meant to fine tune gene expression and their activity reduces
the target proteins only to modest levels. Moreover, after
degrading a target, the Ago-2 bound siRNA is free to attack the
next target molecule, whereas oligos bound to other Agos
presumably need to interact continuously to mediate translational
repression/destabilization. Thus, Ago-2 mediated siRNA effects
are likely to be catalytic and thus more robust than siRNAs bound
to other Agos as well as the miRNA effects. Our results are entirely
in agreement with this hypothesis. Our results have a number of
implications: since siRNAs are distributed between all Agos in
mammalian cells of which only Ago-2 bound siRNA has antiviral
effect, most of the input siRNAs are ineffective and are wasted,
although the actual portion bound to each Ago when all Agos are
expressed is not known. In other words, siRNAs required for
actual antiviral effect is likely to be only a fraction of what appears
to be needed. Moreover, the siRNAs bound to Agos 1, 3 and 4
may interfere with the binding of the endogenous miRNAs,
thereby resulting in toxicities. Thus, if siRNAs can be designed to
be only loaded to Ago-2, it might both improve antiviral efficacy
and at the same time reduce toxicities. In this regard, cellular pre-
miRNA 451 has recently been shown to bypass dicer cleavage to
be directly processed by Ago-2 [33]. Conceivably, antiviral
siRNAs could be designed in the context of pre-miRNA 451 that
is directly processed by Ago2 and incorporated into Ago-2 bound
RISC.
Many viruses also encode miRNAs that are completely or
partially homologous with their viral targets and cellular miRNAs
have also been proposed to affect viral replication [19,20,34].
Although in several cases, the targeted region appears to be in the
39 UTR, several cellular miRNAs are known to target the coding
region to repress the target gene [21,22,23,24]. Although several
cellular miRNAs have also been reported to affect many viral
replication by binding to viral coding region or 39UTR, our results
suggest that synthetic siRNAs designed to mimic miRNA having a
seed match to the viral sequences may not be enough for antiviral
activity in an acute flaviviral infection. This may be because the
miRNA-like effects are generally mild and only serve to
moderately reduce the target protein levels, which may not be
able to affect the abundantly expressed viral proteins. Recently,
dual functional siRNAs that are both completely complementary
to a viral target and at the same time possess seed matches in the
39UTR have been proposed to improve the functionality of siRNA
[35]. Again, the additive effect of seed matches in the coding
region is likely to be minimal in suppressing flaviviral infection.
Figure 1. All 4 Ago proteins bind both fully complementary siRNA and partially complementary miRNA resembling oligos and
repress target gene in reporter assays. Parental ES cells expressing all ago proteins and ES cells expressing individual Ago proteins were
transfected with dual luciferase reporter vector containing dengue virus siRNA target sequences in the Renilla luciferase 39UTR along with fully or
partially complementary dengue virus siRNAs and the dual luciferase expression measured after 24 h of transfection. Rluc/Fluc expression normalized
to control irrelevant GFP siRNA is shown. Error bars represent mean of quadruplicates +/2 SD.
doi:10.1371/journal.pone.0027551.g001
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accumulate in P bodies [29]. In HIV infection, P bodies are
used to suppress infection: miRNA 29 family that represses the
viral replication as well as the viral transcripts associate with P
bodies and disruption of P body components by siRNA results in
enhancing HIV replication [36,37]. In contrast, Dengue and
West Nile virus infection result in the progressive loss of P bodies
and resistance to stress granule formation. Although inhibition of
stress granule formation may be due to the recruitment and
sequestration of TIA-1 and TIAR into the viral replication
complex [31], the reason for loss of P bodies is not known [31].
Our results suggest that disappearance of microscopic P bodies is
not due to the loss of GW182 protein in infected cells. It is
possible that similar to TIAR, GW182 could also be recruited
into the replication complex. Alternatively, other essential
proteins needed for P body formation such as LSm proteins,
RCK/p54 or Ge-1 [29] may be affected. Whatever the
mechanism of loss of P bodies, our results suggest that GW182
protein, which is essential for miRNA-mediated repression is not
affected and both the siRNA and miRNA pathways remain intact
after flaviviral infection. Thus, lack of antiviral effect of miRNA-
structured siRNAs is not due to loss of P bodies, but most likely,
as mentioned earlier because the miRNA mimicking siRNA
effects are too weak to suppress the abundantly expressed
flaviviral proteins.
In summary, robust suppression of viral infection can only be
achieved by completely complementary siRNA bound Ago-2-
mediated target cleavage and miRNA mediated translational
repression/mRNA destabilization or other Ago proteins appear to
have no role in the anti-flaviviral RNAi.
Figure 2. Only Ago-2 bound fully complementary siRNA shows antiviral activity. A, B) ES cells expressing individual Ago proteins were
transfected with fully or partially complementary siRNAs, infected with dengue virus (A) or WNV (B) and virus replication measured by FACS analysis
after 72 h following infection. siGFP was used as negative control. C) WNV particles released into ES supernatant in (B) were quantified by QRT-PCR.
D) Transfection efficacy in different ES cells was assessed using FITC labeled siRNA. E) ES cells were transfected with 2 different anti-WNV siRNAs,
infected with WNV and virus replication determined as in A). Error bars represent mean of duplicates +/- SD.
doi:10.1371/journal.pone.0027551.g002
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siRNAs and miRNA mimicking oligonucleotides
SiRNA and miRNA mimicking oligos were obtained from
Dharmacon (Lafayette, CO). The sense strand sequences from 59
to 39 end were: siFvE
D (siRNA against dengue virus) ggatgtggat-
tatttggaa; miFvE
D (miRNA mimic) ggatgtggtaaatttggaa; siWN-
3UTR (siRNA against WNV 30 UTR) tgtagtgttcatagcaatt; miWN-
3UTR (miRNA mimic against WN 39UTR) tgtagtgtagttagcaatt;
siFvE
JW (siRNA against WNV) gggagcattgacacatgtgca; si6 (siRNA
against WNV), ctgtgacattggagagtca; siDV1 (negative control
siRNA) cagcatattgacgctggga; siGFP (negative control siRNA)
ggctacgtccaggagcgca.
Dual-luciferase constructs and assay
Reporter was constructed by cloning the DNA oligos containing
the target sequence between the XhoI and NotI sites downstream
of the Renilla luciferase gene in the psiCHECK2 vector (Promega,
Maddison, WI). The DNA oligos for the dengue siRNA (siFvE
D)
target ggatgtggattatttggaa was synthesized at IDT.
Ago1-4 expressing ES cells and HeLa cells were cultured as
described previously [9]. One day before transfection, the cells
were trypsinized and diluted to 10
5 cells/ml and seeded in 96 well
plates in a volume of 100 mL/well. Reporter plasmids (20 ng of
psiCHECK2 plasmid harboring the target region) together with
siRNA or miRNA structured oligos (1 pmol siRNA/miRNA
oligos) were cotransfected using Lipofectamine 2000 (Life
Technologies, Carlsbad, CA). After 24 h, Renilla and firefly
luciferase activities were measured according to the manufactur-
er’s instructions using the Dual-Glo luciferase assay kit. The ratio
of Renilla to firefly luminescence was normalized to the negative
control siRNA (siGFP or siDV1). Luminescence activity values
represented an average of four replicates.
Testing siRNA/miRNAs for antiviral activity
The antiviral activity of si/miRNAs was tested as previously
described [25,26]. Briefly, ES cells were seeded in 48-well plates at
4610
4 cells per well one day before transfection. The siRNAs
(8 pmol) were transfected into cells with RNAiMax (Invitrogen)
per the manufacturer’s instructions. 24 hours after transfection,
the cells were infected with Dengue-2 (NGC strain, ATCC) or
West Nile virus (B956 strain, ATCC) (moi=1-5). 72 hours later,
the cells were stained with anti-flavivirus envelope specific
antibody (4G2, ATCC), followed by flow cytometric analysis to
determine inhibition of virus replication.
Hela cells stably expressing WNV replicon
WNV replicon pWIIREPG-Z [38] was transfected into HeLa
cells using lipofectamine 2000. The stably transfected HeLa cells
were selected using DMEM medium supplemented with 300 mg/
ml Zeocin for 5–7 days followed limited dilution cloning. One
clone (HeLa-WNR) expressing GFP and harboring full-length
WNV replicon (as assessed by RT-PCR) was selected.
Immunostaining and Western blot
Untransfected, WNV replicon transfected and WNV or Dengue
virus infected HeLa cells were immunostained for P bodies. Cells
grown on cover slips were washed in PBS, fixed in 4%
paraformaldehyde, permeabilized with 0.5% Triton X-100, and
blocked (2% bovine serum albumin, 5% normal horse serum, and
10 mM glycine in phosphatebuffered saline). The cells were then
incubated with a rabbit anti -DCP1a antibody (Abcam) and West
Nile or DENV-2 specific antibodies (US Biologicals), followed by
incubation with appropriate secondary antibodies (AlexaFluor
594-conjugated anti-rabbit antibody and fluorescein isothiocya-
nate-conjugated anti-mouse antibody (Invitrogen). The cells were
visualized for WN/DENV-2 and DCP1a staining using a Nikon
Eclipse fluorescence microscope.
For Western blot analysis, normal, replicon expressing and virus
infected cell lysates were electrophoresed on 12% Nu-PAGE gels
(Invitrogen) and electroblotted onto polyvinylidene difluoride
membranes (Immobilon-P transfer membrane; Millipore). Follow-
ing a blocking step with Tris-buffered saline containing 0.1%
Tween-20 and 5% dry milk, the membranes were incubated with
Figure 3. Flavivirally infected cells lose microscopic P bodies, but not GW182 and exhibit both si and miRNA-mediated target
repression. A) Uninfected and dengue or West Nile virus infected HeLa cells were stained with DAPI, DCP1a and dengue/WNV antibody and
examined for P bodies by microscopy. B) Control HeLa cells and HeLa cells expressing WNV replicon (HeLa WNR) were tested for GW182 isoform
expression at mRNA level by QRT-PCR (left) and protein level by Western blot (right). C) West Nile replicon expressing HeLa cells were transfected
with luciferase reporter with si/miRNA and analyzed as in Fig 1a. siDV1 represents control irrelevant siRNA. Error bars represent mean of
quadruplicates +/2 SD.
doi:10.1371/journal.pone.0027551.g003
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peroxidase-conjugated secondary antibody (Peirce). Bound horse-
radish peroxidase was visualized with an ECL substrate kit
(Thermo Scientific). Membranes were stripped and reprobed with
a rabbit anti b-actin antibody (Cell Signaling) as a loading control.
QRT-PCR
Total RNA was isolated from HeLa cells and stable HeLa
expressing WNV replicon or from WNV infected ES cell
supernatants using RNeasy kit (Qiagen). Reverse transcription
was performed using superscript III first-strand synthesis superMix
(Invitrogen). Quantitative real-time PCR was performed using a
SYBR green PCR master Mix (Applied Biosystems) on 7900HT
fast real-time PCR system (applied Biosystems). Amplification
conditions were as follows: 95uC for 10 min, followed by 40 cycles
of 95uC for 15 s, and 60uC for 1 min. The forward and reverse
primers to amplify GAPDH were atggggaaggtgaaggtcg and
gggtcattgatggcaacaatatc, and that for TNRC6 A, B and C
isoforms were gaaatgctctggtccgctaca & atctcctcttcactggcaaactca;
ggagcaaaagcacaccacctg & tgctcctgtatcatccatctcg; cccgccgcacctgtct-
ct & ctgctgctctttggtctgc, respectively and for WNV were atcgcc-
ggacttatgttcg & ctttcgctagagcctgtgattt. Relative TNRC6 mRNA
expression was normalized with GAPDH mRNA and calculated
using the dCt method.
Statistical analysis
Student’s t test (two-tailed, assuming equal variances on all
experimental data sets) was used to compare two groups of
independent samples.
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